About Us

Meet Our Team

Christian Walker, MBA, MS

CEO, Founder, and Board Member

View Experience

Christian Walker, MBA, MS

Chief Executive Officer, Founder and Member of Board of Directors: Mr. Walker has over 20 years of entrepreneurial and senior management experience in the commercialization of nerve technologies, most recently working at industry leader AxoGen on regenerative medicine commercialization and business development.

  • Previously he served as Director of the Peripheral Nerve Institute at Walter Reed National Military Medical Center managing multi-site clinical trials in peripheral nerve repair using peripheral nerve allografts and autologous stem cells in humans.
  • He also served as the first Director of the Johns Hopkins Military and Veterans Health Institute. Mr. Walker brings financial and investment experience having served as Principal at Toucan Capital, a $140M VC Fund, focusing on regenerative medicine and cell therapy.
  • Walker also served as EVP of Operations at Telcare (Acquired in 2016), CEO of MedRelief, focusing on stem cell differentiation for the treatment of Osteoporosis, and CEO and Founder of Evacyte an early-stage cancer detection company that won the 2001 KPMG Start-up Stand-Out Award.

Mr. Walker completed his MBA at the Isenberg School of Management at the University of Massachusetts Amherst, a Master’s degree in Biomedical Engineering from the University of Massachusetts Medical School and a Master’s degree in Cell and Molecular Biology from the University of Texas at Austin in the lab whose technology and resulting IP would later become the basis for AxoGen’s lead product Avance.

Jennifer Butler

Chief Commercial Officer

View Experience

Jennifer Butler

Chief Commercial Officer: Throughout her 25 year career, Ms. Butler has spearheaded corporate strategy, business development, and commercial initiatives across diverse therapeutic domains across biopharma.  

  • Her experience includes over a decade of contributions at AstraZeneca/MedImmune, where she held various commercial and corporate strategy roles, including Global Commercial Head of Immuno-Oncology, Multi-Indications. Ms. Butler notably managed the global Respiratory, Inflammatory and Autoimmune (RIA) commercial team supporting R&D investment decisions allocating >$750 million across RIA programs.  Ms. Butler played a pivotal role in the global commercial readiness efforts for Imfinzi / durvalumab, a milestone achievement that saw Imfinzi become AstraZeneca’s first biologics launch in oncology.
  • As EVP, Head of Global Commercial and US – General Manager at Innate Pharma, she established US commercial operations, including site selection, finance, legal, compliance, and HR at Innate Pharma. This groundwork was pivotal in commercializing the company’s first product approved in a rare hematological malignancy (<500 patients)
  • Early in her career, she worked at Merrill Lynch on the Equity and Equity-Linked Capital Markets Team.  She has helped raise capital ranging from angel investments to public capital markets including raising $79 million in a Nasdaq Initial Public Offering (IPO) as a key member of the executive team at Innate Pharma. 

Ms Butler holds a B.A. in Biological Basis of Behavior, with a concentration in Physiology of Neural Systems, from the University of Pennsylvania. She volunteers with several youth sports groups in various roles.

Luis Gutierrez, MBA

Chief Operating Officer, and Board Member

View Experience

Luis T. Gutiérrez, Jr.

Chief Operating Officer and Member of Board of Directors: Mr. Gutierrez brings over 25 years of experience in managing companies in the biopharmaceutical and life sciences industries.   His prior roles include:

  • Chief Commercial Officer of Veranex, Inc., a private-equity backed company created by acquiring and integrating 8 leading providers of regulatory, preclinical, clinicical, and product development services to the medtech industry.  
  • President, CEO, and Board Member of Theranostics Health (now TheraLink Technologies) a molecular diagnostics company that provides proteomic testing services to oncologists, academic institutions, and the biopharmaceutical industry.
  • EVP and CCO of Aptiv Solutions, a company that innovated the designing and executing adaptive clinical trials for developers of biopharmaceutical, medical device, and diagnostic products. He helped position that company for a successful sale to industry leader ICON, PLC.   
  • President of Covance’s Commercialization Services group, where he was responsible for over 800 employees and $100M in revenue. The group he led helped biopharmaceutical and medical technology companies quantify the clinical and economic value of their products.   

Mr. Gutierrez earned a Master’s in Business Administration from the Stanford Graduate School of Business and a Bachelor of Arts Degree from Harvard College. 

Amy Chappell, MD, FAAN

Chief Medical Officer

View Experience

Amy Chappell

Chief Medical Officer: Dr. Chappell is a board certified neurologist with special competence in child neurology and a board-certified lifestyle medicine physician.

  • She graduated from Indiana University Medical School; completed 2 years of pediatrics and an epilepsy fellowship at the Johns Hopkins Medical Center; and completed a neurology residency at Indiana University Medical Center. She was a full time faculty member in the neurology department of the Indiana University Medical Center until being hired as a clinical research physician by Eli Lilly and Company.
  • At Eli Lilly, She designed and conducted clinical trials through all phases of development in a broad range of neurological disorders. She was the lead physician for the development of duloxetine for fibromyalgia which resulted in an FDA approval. She retired from Lilly Research Laboratories in January 2014, after 25 years in clinical research.
  • During her career at Lilly Dr. Chappell continued to practice neurology at the Indiana University Medical Center.

She now practices neurology as a volunteer at the Neighborhood Health Clinic in Naples, FL, and practices lifestyle medicine at the Greater Naples Y. She is a fellow of the American Academy of Neurology and the American College of Sports Medicine, board member of the American Society of Experimental Neurotherapeutics, and a member of the Child Neurology Society, the American College of Lifestyle Medicine and the Society of Tennis Medicine and Science.

Lauren Sabella

Chairperson Of The Board; Current COO, Mannkind; Former COO, CCO, Acorda Therapeutics

John Elfar, MD, MBA

Medical Co-Founder; Chairman of Orthopaedics, Univ. of Arizona

Mark Noble, PhD

Scientific Co-Founder; Professor of Neuroscience, Univ. of Rochester

Matthis Synofzik, MD

Ataxia Neurology Advisor; Professor, University of Tuebingen

Christian Rummey

Translational & Data Sciences; Principal, Clinical Data Science GmbH

Mary Hogan, MPH, MS

Patient Advocacy Advisor; SCA27b Family Member and Founder of SCA27b Foundation

Foundation Partners

Scroll to Top